| 标题 |
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet 作者:Amy E. Colson; Anthony Mills; Moti Ramgopal; Christopher Bettacchi; Olayemi O Osiyemi; et al 出版日期:2026-02-01 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)